SPARCL Study

High Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Physiology

Pathophysiology

Causes

Low HDL
High HDL

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

HDL Laboratory Test

Treatment

Medical Therapy

Prevention

Future or Investigational Therapies

Clinical Trials

Landmark Trials

List of All Trials

Case Studies

Case #1

SPARCL Study On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of SPARCL Study

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on SPARCL Study

CDC on SPARCL Study

SPARCL Study in the news

Blogs on SPARCL Study

Directions to Hospitals Treating High density lipoprotein

Risk calculators and risk factors for SPARCL Study

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

## Objective

[edit | edit source]

To study the effects of statins on incidence of recurrent stroke after a recent episode of stroke or transient ischemic attack

## Methods

[edit | edit source]

Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) was a double blinded study with subjects who had at least one episode of stroke in the last one to six months and LDL levels of 100 to 190 mg/dl with no history of coronary artery disease. These patients were randomly assorted to receive either 80 mg of atorvastatin daily or placebo. The primary end point for the study was first fatal or non-fatal stroke.

## Results

[edit | edit source]

* During the mean follow up period of 4.9 years, 11.2% of patients from the atorvastatin group and 13.1% of patients from the placebo experienced fatal/non-fatal stroke, with a 5 year absolute risk reduction of 2.2%.
* The 5 year absolute risk reduction in major cardiovascular events was 3.5%.
* The overall mortality rates were similar in both the groups.

## Conclusion

[edit | edit source]

Atorvastatin (80 mg daily) reduced the incidence of recurrent stroke and cardiovascular events in patients with a recent episode of stroke or transient ischemic attacks. However, the incidence of hemorrhagic stroke increased in the atorvastatin group.[1]

## References

[edit | edit source]

1. ↑ Amarenco P, Bogousslavsky J, Callahan A; et al. (2006). "High-dose atorvastatin after stroke or transient ischemic attack". The New England Journal of Medicine. 355 (6): 549–59. doi:10.1056/NEJMoa061894. PMID 16899775. Unknown parameter `|month=` ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)

* v
* t
* e

Lipopedia

Basic Science|

Cholesterol • Triglyceride

Lipoprotein metabolism and transport

Lipoprotein: Chylomicron • Chylomicron remnant • HDL • IDL • LDL • Lipoprotein(a) • VLDL • Lipoprotein-X

Apolipoprotein: APOA (1, 2, 4,  5) • APOB ( Apolipoprotein B-48, Apolipoprotein B-100) • APOC (1, 2, 3, 4) • APOD • APOE • APOH • APOJ • APOL • APOM • Apo(a)

Lipoprotein receptor: LDL receptor • Soluble low density lipoprotein receptor-related protein (sLRP) • Apolipoprotein E Receptor 2 • Scavenger receptor • Scavenger receptor A • Scavenger receptor B • VLDL receptor

Lipoprotein enzymes: Lipoprotein lipase • Lipoprotein-associated phospholipase A2 (Lp-PLA2) • Cholesterylester transfer protein ( Acetyl-CoA C-acyltransferase, Lecithin-cholesterol acyltransferase) • Microsomal triglyceride transfer protein • ABCA1

Genes: Low density lipoprotein receptor gene family • Microsomal triglyceride transfer protein • ABCA1

Lipoprotein Disorders|

Lipoprotein disorders

Primary lipoprotein disorders: Familial hyperchylomicronemia (Type I) • Familial hypercholesterolemia (Type IIA) • Familial combined hyperlipidemia (Type IIB) • Dysbetalipoproteinemia (Type III) • Primary hypertriglyceridemia (Type IV) • Mixed hyperlipoproteinemia (Type V)

Secondary lipoprotein disorders

Abnormal Laboratory Lipid Profile|

Low chylomicron • Low chylomicron remnant • Low HDL • Low IDL • Low LDL • Low lipoprotein(a) • Low VLDL

High chylomicron • High chylomicron remnant • High HDL • High IDL • High LDL • High Lipoprotein(a) • High VLDL
*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template